# Pharmacokinetics of Two Eletriptan Oral Formulations Given With and Without Water and the Commercial Tablet Formulation Given With Water

> **NCT00871806** · PHASE1 · COMPLETED · sponsor: **Pfizer's Upjohn has merged with Mylan to form Viatris Inc.** · enrollment: 20 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** Commercial tablet with water
- **DRUG:** ODT #1 without water
- **DRUG:** ODT #2 without water
- **DRUG:** ODT #1 with water
- **DRUG:** ODT #2 with water

## Key facts

- **NCT ID:** NCT00871806
- **Lead sponsor:** Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-04
- **Primary completion:** 2009-04
- **Final completion:** 2009-04
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2021-01-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00871806

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00871806, "Pharmacokinetics of Two Eletriptan Oral Formulations Given With and Without Water and the Commercial Tablet Formulation Given With Water". Retrieved via MORVS 2026-10-19 from https://api.morvs.ai/clinical/NCT00871806. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*